Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of pharmacy-benefit manager Express Scripts (Nasdaq: ESRX) climbed 10% on Thursday after cutting its profit forecast less than expected.

So what: The shares have taken a beating on cost concerns associated with its proposed $29 billion buyout of rival MedcoHealth Solutions (NYSE: MHS), but the full-year cut -- Express Scripts now expects adjusted earnings of $2.95-$3.05 per share, versus its prior forecast of $3.15-$3.25 -- isn't nearly as bad as investors had feared. Of course, the stock is still off more than 30% since announcing the deal in late July, so Mr. Market hasn't exactly applauded the move just yet.

Now what: Express Scripts remains a pretty attractive long-term opportunity. "In spite of near-term headwinds and a challenging macroeconomic environment," said Chairman and CEO George Paz, "we remain confident we are well-positioned for continued growth." In fact, the company's fiscal forecasts through 2014 -- disclosed in a securities filing on the merger -- were also much higher than analysts had expected, offering investors even more comfort regarding the Medco buy.

Interested in more info on Express Scripts? Add it to your watchlist.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.